Key result
Activation of the murine EP3 receptor by low concentrations of PGE2 enhances platelet aggregation by inhibiting cAMP production, and EP3 deficiency protects against venous thrombosis in vivo.
Why the study?
Does activation of the EP3 receptor for PGE2 promote platelet aggregation and intravascular clot formation in a murine model?
Population
Murine model of venous inflammation and platelets
Design
Preclinical
Authors
Loading...
EP3 may be a novel antithrombotic target; leaves open translation to human venous thrombosis prevention.
Does activation of the EP3 receptor for PGE2 promote platelet aggregation and intravascular clot formation in a murine model?
p-value: p=<0.01
The study identifies the EP3 receptor as the key mediator of PGE2-induced platelet aggregation at low concentrations, providing a mechanistic link between local inflammation and thrombosis.
Fabre et al. (2001) studied Platelet aggregation and thrombosis. Prostaglandin E2 (PGE2) and receptor deficiency vs. Wild-type platelets or vehicle was evaluated on Platelet aggregation and in vivo thrombus formation score (p=<0.01). Activation of the murine EP3 receptor by low concentrations of PGE2 enhances platelet aggregation by inhibiting cAMP production, and EP3 deficiency protects against venous thrombosis in vivo.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: